Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition

Brain Research

Volumn 1197, Issue , 2008, Pages 47-62

  Gu, Guibao ^a   Lorrain, Daniel S ^a   Wei, Hongbing ^a   Cole, Rebecca L ^a   Zhang, Xin ^a   Daggett, Lorrie P ^a   Schaffhauser, Herve J ^a   Bristow, Linda J ^a   Lechner, Sandra M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anxiety; Excitatory amino acid; Glutamate; Limbic system; Metabotropic glutamate receptor; mGlu2

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3;

4 AMINOBUTYRIC ACID RELEASE; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DENTATE GYRUS; EMOTION; FOREBRAIN; GLIA; HIPPOCAMPUS; IN SITU HYBRIDIZATION; LIMBIC SYSTEM; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RAT; THALAMUS;

ANIMALS; BLOTTING, WESTERN; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICRODIALYSIS; MICROSCOPY, CONFOCAL; PROSENCEPHALON; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER; TRANSFECTION;

RATTUS;

EID: 39149083048     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.12.057     Document Type: Article

References (67)

1. Alexander G.M., and Godwin D.W. Presynaptic inhibition of corticothalamic feedback by metabotropic glutamate receptors. J. Neurophysiol. 94 1 (2005) 163-175
2. Beracochea D.J., and Krazem A. Effects of mammillary body and mediodorsal thalamic lesions on elevated plus maze exploration. Neuroreport 2 12 (1991) 793-796
3. Capogna M. Distinct properties of presynaptic group II and III metabotropic glutamate receptor-mediated inhibition of perforant pathway-CA1 EPSCs. Eur. J. Neurosci. 19 10 (2004) 2847-2858
4. Charney D.S., and Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit. Rev. Neurobiol. 10 3-4 (1996) 419-446
5. Conn P.J., and Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 205-237
6. Cox C.L., and Sherman S.M. Glutamate inhibits thalamic reticular neurons. J. Neurosci. 19 15 (1999) 6694-6699
7. Crook J.M., Akil M., Law B.C., Hyde T.M., and Kleinman J.E. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiatry 7 2 (2002) 157-164
8. Cube R.V., Vernier J.M., Hutchinson J.H., Gardner M.F., James J.K., Rowe B.A., Schaffhauser H., Daggett L., and Pinkerton A.B. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGlu2). Bioorg. Med. Chem. Lett. 15 9 (2005) 2389-2393
9. Doleviczenyi Z., Halmos G., Repassy G., Vizi E.S., Zelles T., and Lendvai B. Cochlear dopamine release is modulated by group II metabotropic glutamate receptors via GABAergic neurotransmission. Neurosci. Lett. 385 2 (2005) 93-98
10. Dunayevich, E., Erickson, J., Levine, L., Landbloom, R., Schoepp, D.D., Tollefson, G.D., Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2007 Aug 22 on line publication.
11. Feeley Kearney J.A., and Albin R.L. mGlus: a target for pharmacotherapy in Parkinson disease. Exp. Neurol. 184 Suppl 1 (2003) S30-S36
12. Ferris P., Seward E., and Dawson G.R. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze. J. Psychopharmacol. 15 2 (2001) 76-82
13. Govek S.P., Bonnefous C., Hutchinson J.H., Kamenecka T., McQuiston J., Pracitto R., Zhao L.X., Gardner M.F., James J.K., Daggett L.P., Rowe B.A., Schaffhauser H., Bristow L.J., Campbell U.C., Rodriguez D.E., and Vernier J.M. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGlu2): efficacy in an animal model for schizophrenia. Bioorg. Med. Chem. Lett. 15 18 (2005) 4068-4072
14. Grillon C., Cordova J., Levine L.R., and Morgan III C.A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 168 4 (2003) 446-454
15. Grueter B.A., and Winder D.G. Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. Neuropsychopharmacology 30 7 (2005) 1302-1311
16. Gu G., Varoqueaux F., and Simerly R.B. Hormonal regulation of glutamate receptor gene expression in the anteroventral periventricular nucleus of the hypothalamus. J. Neurosci. 19 8 (1999) 3213-3222
17. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., and Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284 2 (1998) 651-660
18. Higgins G.A., Ballard T.M., Kew J.N., Richards J.G., Kemp J.A., Adam G., Woltering T., Nakanishi S., and Mutel V. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46 7 (2004) 907-917
19. Johnson M.P., Baez M., Jagdmann Jr. G.E., Britton T.C., Large T.H., Callagaro D.O., Tizzano J.P., Monn J.A., and Schoepp D.D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 46 15 (2003) 3189-3192
20. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., McKinzie D.L., Nisenbaum E.S., Tizzano J.P., and Schoepp D.D. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179 1 (2005) 271-283
21. Kilbride J., Huang L.Q., Rowan M.J., and Anwyl R. Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. Eur. J. Pharmacol. 356 2-3 (1998) 149-157
22. Kilbride J., Rush A.M., Rowan M.J., and Anwyl R. Presynaptic group II mGlu inhibition of short-term depression in the medial perforant path of the dentate gyrus in vitro. J. Neurophysiol. 85 6 (2001) 2509-2515
23. Kuhar M.J. Neuroanatomical substrates of anxiety: a brief survey. Trends Neurosci. 9 (1986) 307-311
24. Laurie D.J., Gray A.M., and Pratt J.A. Influence of mammillary body lesions on the effects of diazepam and FG 7142 in the elevated plus-maze test for anxiety. Neurosci. Lett., Suppl. 38 (1990) S105
25. Lin H.C., Wang S.J., Luo M.Z., and Gean P.W. Activation of group II metabotropic glutamate receptors induces long-term depression of synaptic transmission in the rat amygdala. J. Neurosci. 20 24 (2000) 9017-9024
26. Linden A.M., Greene S.J., Bergeron M., and Schoepp D.D. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29 3 (2004) 502-513
27. Linden A.M., Shannon H., Baez M., Yu J.L., Koester A., and Schoepp D.D. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology (Berl) 179 1 (2005) 284-291
28. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., and Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117 3 (2003) 697-706
29. Marek G.J. Metabotropic glutamate 2/3 receptors as drug targets. Curr. Opin. Pharmacol. 4 1 (2004) 18-22
30. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., and Aghajanian G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292 1 (2000) 76-87
31. Marino M.J., and Conn P.J. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr. Opin. Pharmacol. 6 1 (2006) 98-102
32. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54 5 Suppl 1 (2005) 20-23
33. Mitra R., Jadhav S., McEwen B.S., Vyas A., and Chattarji S. Stress duration modulates the spatiotemporal patterns of spine formation in the basolateral amygdala. Proc. Natl. Acad. Sci. U. S. A. 102 26 (2005) 9371-9376
34. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174 1 (2004) 39-44
35. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., and Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 40 4 (1997) 528-537
36. Moran M.M., McFarland K., Melendez R.I., Kalivas P.W., and Seamans J.K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J. Neurosci. 25 27 (2005) 6389-6393
37. Nakanishi S., Masu M., Bessho Y., Nakajima Y., Hayashi Y., and Shigemoto R. Molecular diversity of glutamate receptors and their physiological functions. EXS 71 (1994) 71-80
38. Neki A., Ohishi H., Kaneko T., Shigemoto R., Nakanishi S., and Mizuno N. Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGlu2, in the rat brain: an immunohistochemical study with a monoclonal antibody. Neurosci. Lett. 202 3 (1996) 197-200
39. Nestler E.J., Hyman S.E., and Malenka R.C. Molecular Neuropharmacology-a foundation for Clinical Neuroscience (2001), The McGraw-Hill Companies, Inc, New York 327-350
40. Ohishi H., Shigemoto R., Nakanishi S., and Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGlu2, in the central nervous system of the rat. Neuroscience 53 4 (1993) 1009-1018
41. Ohishi H., Shigemoto R., Nakanishi S., and Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J. Comp. Neurol. 335 2 (1993) 252-266
42. Ohishi H., Neki A., and Mizuno N. Distribution of a metabotropic glutamate receptor, mGlu2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody. Neurosci. Res. 30 1 (1998) 65-82
43. Ozawa S., Kamiya H., and Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54 5 (1998) 581-618
44. Papez J.W. A proposed mechanism of emotion. Arch. Neurol. Psychiat. 38 (1937) 725-743
45. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic Press, San Diego
46. Petralia R.S., Wang Y.X., Niedzielski A.S., and Wenthold R.J. The metabotropic glutamate receptors, mGlu2 and mGlu3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71 4 (1996) 949-976
47. Pinkerton A.B., Vernier J.M., Schaffhauser H., Rowe B.A., Campbell U.C., Rodriguez D.E., Lorrain D.S., Baccei C.S., Daggett L.P., and Bristow L.J. Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiators for the metabotropic glutamate 2 receptor. J. Med. Chem. 47 18 (2004) 4595-4599
48. Poisik O., Raju D.V., Verreault M., Rodriguez A., Abeniyi O.A., Conn P.J., and Smith Y. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 49 Suppl. 1 (2005) 57-69
49. Pratt J.A. The neuroanatomical basis of anxiety. Pharmacol. Ther. 55 2 (1992) 149-181
50. Rudd M.T., and McCauley J.A. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGlu2). Curr. Top. Med. Chem. 5 9 (2005) 869-884
51. Schaffhauser H., Rowe B.A., Morales S., Chavez-Noriega L.E., Yin R., Jachec C., Rao S.P., Bain G., Pinkerton A.B., Vernier J.M., Bristow L.J., Varney M.A., and Daggett L.P. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64 4 (2003) 798-810
52. Schoepp, D.D., 2004. Case study: utility of metabotropic glutamate agonists in psychiatric illness. 5th World Congress on Stress:Abs 120.
53. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., and Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6 3 (2003) 189-197
54. Schoppa N.E., and Westbrook G.L. Modulation of mEPSCs in olfactory bulb mitral cells by metabotropic glutamate receptors. J. Neurophysiol. 78 3 (1997) 1468-1475
55. Shibata K., Kataoka Y., Yamashita K., and Ueki S. An important role of the central amygdaloid nucleus and mammillary body in the mediation of conflict behavior in rats. Brain Res. 372 1 (1986) 159-162
56. Shigemoto R., Kinoshita A., Wada E., Nomura S., Ohishi H., Takada M., Flor P.J., Neki A., Abe T., Nakanishi S., and Mizuno N. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 17 19 (1997) 7503-7522
57. Shigemoto R., and Mizuno N. In: Ottersen O., and Storm-Mathisen J. (Eds). Metabotropic Glutamate Receptors-Immunocytochemical and In Situ Hybridization Analyses (2000), Elsevier, Amsterdam 63-98
58. Shu S.Y., Ju G., and Fan L.Z. The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neurosci. Lett. 85 2 (1998) 169-171
59. Spooren W.P., Schoeffter P., Gasparini F., Kuhn R., and Gentsch C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 435 2-3 (2002) 161-170
60. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev., Drug Discov. 4 2 (2005) 131-144
61. Tamaru Y., Nomura S., Mizuno N., and Shigemoto R. Distribution of metabotropic glutamate receptor mGlu3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 106 3 (2001) 481-503
62. Testa C.M., Standaert D.G., Young A.B., and Penney Jr. J.B. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 14 5 Pt 2 (1994) 3005-3018
63. Tizzano J.P., Griffey K.I., and Schoepp D.D. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol. Biochem. Behav. 73 2 (2002) 367-374
64. Turner J.P., and Salt T.E. Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro. Neuroscience 122 2 (2003) 459-469
65. Wada E., Shigemoto R., Kinoshita A., Ohishi H., and Mizuno N. Metabotropic glutamate receptor subtypes in axon terminals of projection fibers from the main and accessory olfactory bulbs: a light and electron microscopic immunohistochemical study in the rat. J. Comp. Neurol. 393 4 (1998) 493-504
66. Walker D.L., Rattiner L.M., and Davis M. Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav. Neurosci. 116 6 (2002) 1075-1083
67. Yokoi M., Kobayashi K., Manabe T., Takahashi T., Sakaguchi I., Katsuura G., Shigemoto R., Ohishi H., Nomura S., Nakamura K., Nakao K., Katsuki M., and Nakanishi S. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 273 5275 (1996) 645-647